Please assess the completion status of the following clinical trial:

Trial Title: Tezepelumab Home Use Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 12 to 80 years.~* Documented physician-diagnosed asthma for at least 12 months.~* Evidence of asthma as documented by post BD (albuterol/salbutamol) reversibility of FEV1 ≥ 12% AND ≥200 mL (15-60 min after administration of 4 puffs of albuterol/salbutamol), documented either: in the previous 12 months prior to V1, OR demonstrated at V1, V1A, or at V2.~* Documented history of current treatment with medium- or high-dose ICS for at least 6 months and at least one additional asthma controller medication according to standard practice of care. ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily.~* Morning pre-BD FEV1 of \>50% predicted normal at Visit 1, Visit 1A, or Visit 2.~Exclusion Criteria:~* Clinically important pulmonary or systemic diseases other than asthma.~* History of cancer except basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma of the cervix within 12 months prior to Visit 1.~* Acute upper or lower respiratory infection requiring antibiotics or antiviral medications finalized \<2 weeks before Visit 1 or during screening/run-in period.~* A helminth parasitic infection diagnosed within 6 months that is untreated or is unresponsive to the standard of care.~* Smoking history of ≥10 pack years, (includes vaping and e-cigarettes)~* History of chronic alcohol or drug abuse.~* Tuberculosis requiring treatment within 12 months prior to V1.~* History of HIV, Hepatitis B or Hepatitis C.~* Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives.~* Bronchial thermoplasty in 24 months prior to V1.~* Anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy.~* Evidence of active liver disease (e.g. jaundice, AST, ALT or ALP \>2 times upper limit of normal), ongoing liver disease or inexplicably elevated liver chemistry values.~* Pregnant, breastfeeding or lactating women.~* Non-leukocyte depleted whole blood transfusion in 120 days prior to visit 1.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (AI) (Type: EXPERIMENTAL): Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
- Tezepelumab (APFS) (Type: EXPERIMENTAL): Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

Based on this trial design, predict the completion outcome and termination type (if applicable).